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1. 
IDENTIFICATION OF 3-KETOSTEROD 
9-ALFA-HYDROXYLASE GENES AND 
MCROORGANISMS BLOCKED IN 
3-KETOSTEROID 9-ALFA-HYDROXYLASE 
ACTIVITY 5 
This application is a division of application of U.S. appli 
cation Ser. No. 10/504,034, which claims priority based on 
International Patent Application No. PCT/EP2003/50025, 
filed on Feb. 19, 2003, and European Patent Application No. 10 
02075723.3, filed Feb. 21, 2002. 
FIELD OF THE INVENTION 
The invention relates to isolated polynucleotide sequences 15 
encoding 3-ketosteroid 9C-hydroxylase components, to 
microorganisms blocked in 3-ketosteroid 9C-hydroxylase 
activity, to a method for the preparation of said microorgan 
isms, and to the use of such microorganisms in steroid A'-de 
hydrogenation. 2O 
BACKGROUND OF THE INVENTION 
To date very limited knowledge is available on 3-ketoster 
oid 9C.-hydroxylase (KSH), the enzyme performing the 25 
9C.-hydroxylation of 4-androstene-3,17-dione (AD) and 1,4- 
androstadiene-3,17-dione (ADD) in microbial sterol/steroid 
degradation. No nucleotide sequences of the genes encoding 
KSH components have been reported. Furthermore, difficul 
ties are faced during enzyme purification procedures (Chang, 30 
F. N. et al. Biochemistry (1964) 3:1551-1557; Strijewski, A. 
Eur. J. Biochem. (1982) 128:125-135). A three-component 
monooxygenase with KSH activity has been partially purified 
from Nocardia sp. M117 and was found to constitute a three 
component enzyme system, composed of a flavoprotein 35 
reductase and two ferredoxin proteins (Strijewski, A.Eur. J. 
Biochem. (1982) 128:125-135). In Arthrobacter oxydans 
317, 9C.-hydroxylation of the steroid poly-cyclic ring struc 
ture appeared plasmid-borne (Dutta, R. K. et al. J. Basic 
Microbiol. (1992) 32:317-324). Nucleotide sequence analy- 40 
sis of the plasmid, however, was not reported. 
The lack of genetic data has hampered the construction of 
molecularly defined mutant strains with desired properties 
(i.e. blocked 9C-hydroxylation of steroids) by genetic engi 
neering. Mutants have been isolated by classical mutagen- 45 
esis, but these strains usually are inadequate in industrial 
processes mostly due to genetic instability and/or low bio 
conversion efficiencies. Molecularly defined mutants have 
advantages compared to mutants generated by classical 
mutagenesis. The constructed mutants are genetically stable 50 
and the introduced mutations are well-defined genetic modi 
fications. Construction of genetically engineered strains 
make the widespread use of chemical agents to block 9C-hy 
droxylation (e.g. C.C.-dipyridyl, o-phenanthroline) obsolete. 
Chemical agents used to block KSH activity mostly are not 55 
reaction specific and inhibit other important enzymatic reac 
tions (e.g. Sterol 26-hydroxylation in sterol side chain degra 
dation), which may have negative effects on sterol bioconver 
sion efficiency. The use of defined mutants by genetic 
engineering overcomes these problems. 60 
3-Ketosteroid 9C.-hydroxylase (KSH) is a key-enzyme in 
the microbial steroid ring B-opening pathway. KSH catalyzes 
the conversion of AD into 9C.-hydroxy-4-androstene-3,17 
dione (9CHAD) and ADD into the chemically unstable com 
pound 9CHADD. KSH activity has been found in many 65 
bacterial genera (Martin, C. K. A. Adv. Appl. Microbiol. 
(1977) 22: 29-58; Kieslich, K. J Basic Microbiol. (1985) 25: 
2 
461-474; Mahato, S. B. et al. Steroids (1997) 62: 332-345): 
e.g. Rhodococcus (Datcheva, V. K. et al. Steroids (1989) 
54:271-286: Van der Geize et al. FEMS Microbiol. Lett. 
(2001) 205: 197-202, Nocardia (Strijewski, A. Eur. J. Bio 
chem. (1982) 128:125-135), Arthrobacter (Dutta, R. K. etal. 
J. Basic Microbiol. (1992) 32:317-324) and Mycobacterium 
(Wovcha, M. G. etal. Biochim Biophys Acta (1978) 531:308 
321). Bacterial strains lacking KSH activity are being con 
sidered important in sterol/steroid biotransformation. 
Mutants blocked in KSH activity will be able to perform only 
the KSTD (3-ketosteroid A'-dehydrogenase) reaction, 
thereby allowing selective A'-dehydrogenation of steroid 
compounds. Examples are the cortisol biotransformation into 
prednisolone and the AD biotransformation into ADD. Sterol 
bioconversion by mutants blocked at the level of steroid 
9C-hydroxylation may also carry out a selective degradation 
of the sterol side chain thereby accumulating AD and/or ADD 
which are excellent precursors for the synthesis of bioactive 
steroid hormones. 
According to one aspect of the present invention, the iso 
lated polynucleotide sequences of two genes, designated 
kshA and kshB of Rhodococcus erythropolis are now pro 
vided: SEQID NO:1 and SEQID NO:2, respectively. KshA 
protein is encoded by nucleotides 499-1695 of SEQID NO:1 
and KshB protein by nucleotides 387-1427 of SEQID NO:2. 
Thus, in particular preferred are polynucleotides comprising 
the complete coding DNA sequences of the nucleotides 499 
1695 of SEQ ID NO:1 and of the nucleotides 387-1427 of 
SEQ ID NO:2, respectively. 
Furthermore, to accommodate codon variability the inven 
tion also includes sequences coding for the same amino acid 
sequences of the Ksh A protein and the KshB protein. Also 
portions of the coding sequences coding for individual 
domains of the expressed protein are part of the invention as 
well as allelic and species variations thereof. Sometimes, a 
gene is expressed as a splicing variant, resulting in the inclu 
sion of an additional exon sequence, or the exclusion of an 
exon. Also a partial exon sequence may be included or 
excluded. A gene may also be transcribed from alternative 
promotors that are located at different positions within a gene, 
resulting in transcripts with different 5' ends. Transcription 
may also terminate at different sites, resulting in different 3' 
ends of the transcript. These sequences as well as the proteins 
encoded by these sequences all are expected to perform the 
same or similar functions and form also part of the invention. 
The sequence information as provided herein should not be so 
narrowly construed as to require inclusion of erroneously 
identified bases. The specific sequence disclosed herein can 
be readily used to isolate the complete genes which in turn can 
easily be subjected to further sequence analyses thereby iden 
tifying sequencing errors. 
The present invention further relates to polynucleotides 
having slight variations or having polymorphic sites. Poly 
nucleotides having slight variations encode polypeptides 
which retain the same biological function or activity as the 
natural, mature protein. 
DETAILED DESCRIPTION OF THE INVENTION 
The DNA according to the invention may be obtained from 
cDNA using suitable probes derived from SEQ ID NO:1 or 
SEQ ID NO:2. Alternatively, the coding sequence might be 
genomic DNA, or prepared using DNA synthesis techniques. 
The polynucleotide may also be in the form of RNA. If the 
polynucleotide is DNA, it may be in single stranded or double 
Stranded form. The single strand might be the coding strand or 
the non-coding (anti-sense) strand. 
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The present invention further relates to polynucleotides 
which have at least 70%, preferably 80%, more preferably 
90%, even more preferred 95%, and highly preferably 98% 
and most preferred at least 99% identity with the entire DNA 
sequence of the nucleotides 499-1695 of SEQID NO:1 and of 
the nucleotides 387-1427 of SEQ ID NO:2, respectively. 
Such polynucleotides encode polypeptides which retain the 
same biological function or activity as the natural, mature 
protein. Alternatively, also fragments of the above mentioned 
polynucleotides which code for domains of the protein which 
still are capable of binding to substrates are embodied in the 
invention. 
The percentage of identity between two sequences can be 
determined with programs such as ClustalW 1.7 (Thompson 
J. D., et al. Nucleic Acids Res. (1994) 22: 4673-4680: 
“CLUSTALW: improving the sensitivity of progressive mul 
tiple sequence alignment through sequence weighing, posi 
tion-specific gap penalties and weight matrix.) used in 
default settings. The percentage identity generally is defined 
by the number of identical residues between the two 
sequences divided by the total number of residuesof the 
known sequence. 
Similarity is defined as a combination of identity together 
with all semi-conserved amino acid residues in the alignment 
according to the groups as defined in ClustalW 1.7: 
*-identity—indicates positions which have a single, fully 
conserved residue 
:=semi-conserved indicates that one of the following 
strong groups is fully conserved. STA, NEQK, NHQK, 
NDEQ, QHRK, MILV, MILF, HY, FYW. 
=semi-conserved-indicates that one of the following 
weaker groups is fully conserved. CSA, ATV. SAG, 
STNK, STPA, SGND, SNDEQK, NDEQHK, NEQHRK, 
FVLIM, HFY. 
These are all the positively scoring groups that occur in the 
Gonnet Pam250 matrix. 
Also within the scope of this invention are functional 
homologues of the new genes e.g. in the family of Actino 
mycetales (e.g. Rhodococcus, Nocardia, Arthrobacter; 
Corynebacterium and Mycobacterium). 
In order to identify Such genes with similar action in other 
microorganisms, any method for detection of (poly)nucle 
otides known in the art for such purpose is included herewith. 
For example, nucleotide elongation methods/amplification 
methods may be considered, but also. Such method may com 
prise the steps of hybridizing to a sample a probe specific for 
a polynucleotide encoding an amino acid sequence of Ksha 
or KshBunderconditions effective for said probe to hybridize 
specifically to said polynucleotide and determining the 
hybridization of said probe to polynucleotides in said sample. 
The term “specific’ in this respect means that the majority of 
hybridization takes place with a polynucleotide of this inven 
tion. Preferably, said probe comprises at least 25 of the nucle 
otides of SEQID NO:1 or SEQID NO:2. More preferred, the 
probe comprises 50, and in particular preferred more than 
100, nucleotides of SEQ ID NO:1 or SEQ ID NO:2. Most 
preferred, the probe consists of a polynucleotide of nucle 
otides selected from the nucleotides 499-1695 of SEQ ID 
NO:1 and of the nucleotides 387-1427 of SEQ ID NO:2, 
respectively. Appropriate stringency conditions which pro 
mote DNA hybridization, for example, 6.0 x sodium chloride/ 
sodium citrate (SSC) at about 45° C., followed by a wash of 
2.0xSSC at 50° C., are known to those skilled in the art or can 
be found in Current Protocols in Molecular Biology, John 
Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. For example, the salt 














stringency of about 2.0xSSC at 50° C. to a high stringency of 
about 0.2xSSC at 50° C. In addition, the temperature in the 
wash step can be increased from low Stringency conditions at 
room temperature, about 22°C., to high Stringency conditions 
at about 65° C. 
Alternatively, the polynucleotides of this invention may 
also be used for targeting specific genes, e.g. for the purpose 
of gene disruption in other species (see for example WO 
01/31050 and references cited therein). 
The sequence of the newly identified polynucleotide of the 
present invention, SEQID NO:1 and SEQID NO:2 may also 
be used in the preparation of vector molecules for the expres 
sion of the encoded protein in suitable host cells. A wide 
variety of host cell and cloning vehicle combinations may be 
usefully employed in cloning the nucleic acid sequences cod 
ing for the proteins Ksha or KshB or parts thereof. For 
example, useful cloning vehicles may include chromosomal, 
non-chromosomal and synthetic DNA sequences such as 
various known bacterial plasmids and wider host range plas 
mids and vectors derived from combinations of plasmids and 
phage or virus DNA. Vehicles for use in expression of the 
polynucleotides of the present invention or a part thereof 
comprising a functional domain will further comprise control 
sequences operably linked to the nucleic acid sequence cod 
ing for the protein. Such control sequences generally com 
prise a promoter sequence and sequences which regulate 
and/or enhance expression levels. Of course control and other 
sequences can vary depending on the host cell selected. 
Suitable expression vectors are for example bacterial or 
yeast plasmids, wide host range plasmids and vectors derived 
from combinations of plasmid and phage or virus DNA. Vec 
tors derived from chromosomal DNA are also included. Fur 
thermore an origin of replication and/or a dominant selection 
marker can be present in the vector according to the invention. 
The vectors according to the invention are suitable for trans 
forming a host cell. Integrative vectors may also be regarded 
as Suitable expression vehicles. 
Recombinant expression vectors comprising DNA of the 
invention as well as cells transformed with said DNA or said 
expression vector also form part of the present invention. 
Suitable host cells according to the invention are bacterial 
host cells, yeast and other fungi, insect, plant or animal host 
cells such as Chinese Hamster Ovary cells or monkey cells or 
human cell lines. Thus, a host cell which comprises DNA or 
expression vector according to the invention is also within the 
Scope of the invention. The engineered host cells can be 
cultured in conventional nutrient media which can be modi 
fied e.g. for appropriate selection, amplification or induction 
of transcription. The culture conditions such as temperature, 
pH, nutrients etc. are well known to those ordinary skilled in 
the art. 
The techniques for the preparation of DNA or the vector 
according to the invention as well as the transformation or 
transfection of a host cell with said DNA or vector are stan 
dard and well known in the art, see for instance Sambrook et 
al., Molecular Cloning: A laboratory Manual. 2nd Ed., Cold 
Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1989. 
In another aspect of the invention, there is provided for a 
protein comprising the amino acid sequence encoded by any 
of the above described DNA molecules. Preferably, the pro 
tein according to the invention comprises an amino acid 
sequence encoded by the nucleotides 499-1695 of SEQ ID 
NO:1 or of the nucleotides 387-1427 of SEQ ID NO:2, 
respectively. Also part of the invention are proteins resulting 
from post translational processing, which proteins are 
encoded by the polynucleotide of this invention. 
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Also functional equivalents, that is proteins homologous to 
amino acid sequences of Ksha and KshB or parts thereof 
having variations of the sequence while still maintaining 
functional characteristics, are included in the invention. 
The variations that can occur in a sequence may be dem 
onstrated by (an) amino acid difference(s) in the overall 
sequence or by deletions, Substitutions, insertions, inversions 
or additions of (an) amino acid(s) in said sequence. Amino 
acid substitutions that are expected not to essentially alter 
biological activities, have been described. Amino acid 
replacements between related amino acids or replacements 
which have occurred frequently in evolution are, inter alia 
Ser/Ala, Ser/Gly, Asp/Gly, Asp/ASn, Ile/Val (see Dayhof. M. 
D., Atlas of protein sequence and structure, Nat. Biomed. 
Res. Found. Washington D.C., 1978, Vol. 5, suppl. 3). Based 
on this information Lipman and Pearson developed a method 
for rapid and sensitive protein comparison(Science, 1985, 
227, 1435-1441) and determining the functional similarity 
between homologous polypeptides. It will be clear that also 
polynucleotides coding for Such variants are part of the inven 
tion. 
The polypeptides according to the present invention also 
include polypeptides comprising an amino acid sequence 
encoded by the nucleotides 499-1695 of SEQID NO:1 or of 
the nucleotides 387-1427 of SEQID NO:2, respectively, but 
further polypeptides with a similarity of at least 70%, prefer 
ably 80%, more preferably 90%, and even more preferred 
95%. Also portions of such polypeptides still capable of con 
ferring biological effects are included. 
Another aspect of the present invention are genetically 
modified microorganisms. For the construction of mutant 
strains incapable of 9o-hydroxylation, the genes encoding 
KSH activity must be identified and their nucleotide sequence 
must be known. The two genes of this invention, designated 
kshA and kshB, were identified in Rhodococcus erythropolis 
SQ1 to encode KSH. These genes were cloned by functional 
complementation of two UV mutants, designated Strains 
RG1-UV26 and RG1-UV39, both impaired in 9o-hydroxy 
lation of AD(D). They were isolated via an extensive screen 
ing of UV irradiated cells of R. erythropolis strain RG1 (van 
der Geize, R. et al. FEMS Microbiol. Lett. Submitted 2001), 
a kstD (encoding 3-ketosteroid A'-dehydrogenase-KSTD1) 
gene deletion mutant of strain SQ1. Strains RG1-UV26 and 
RG1-UV39 were unable to grow on AD and ADD, but grew 
normally on 9CHAD, indicating deficient KSH activity. 
For functional complementation of the KSH deficient 
mutant strains RG1-UV26 and RG1-UV39 and cloning of the 
kshA and kshB genes, a genomic library of R. erythropolis 
RG1 was constructed using Rhodococcus-E. coli shuttle vec 
torpRESQ (FIG. 1). Sau3A digested chromosomal DNA of 
R. erythropolis RG1 was sized by sucrose gradient to 6-10 kb 
and ligated into BglII digested pRESQ. Transformation of E. 
coli Top 10F (Invitrogen Corp.) with this ligation mixture 
generated a gene library of approximately 15,000 transfor 
mants in which approximately 90% of the constructs con 
tained insert. An average insert size of 6 kb was estimated. No 
complications with stability or rearrangements were appar 
ent. The gene library represents the complete genome 
(p>0.99) assuming a genome size of approximately 6 Mb. 
Introducing the R. erythropolis RG1 genomic library into 
strains RG1-UV39 and RG1-UV26 and subsequent screen 
ing for complementation of KSH deficiency, resulted in the 
cloning of two independent DNA fragments containing the 
kshA gene and the kshB gene, respectively (FIG. 2). Analysis 
of these genes revealed that kshA encodes a 398 amino acid 
protein (Ksha). KshA showed high similarity (58% identity: 













Rv3526 (DDBJ/EMBL/GenBank accession no. CAB05051) 
in Mycobacterium tuberculosis (Cole, S. T. et al Nature 
(1998) 393: 537-544). Rv3526 is thus expected to be the 
homologue of kshA in M. tuberculosis. Comparison of the 
obtained nucleotide sequence of kshA to databases further 
revealed that kshA is identical (97%) to a hypothetical gene 
(ORF12), found by Maeda, M. etal (Appl. Environ. Micro 
biol. (1995) 61:549-555) in R. erythropolis strain TA421 
(DDBJ/EMBL/GenBank accession no. D88013) upstream of 
bphCl (FIG. 3). In analogy with the molecular organization 
found in strain TA421, a hypothetical ORF11, identified in 
this strain downstream of ORF12, was also identified down 
stream ofkshA instrain SQ1. The nucleotide sequences of the 
DNA fragments of strain SQ1 and strain TA421 were there 
fore merged and the resulting theoretical nucleotide sequence 
was used for the successful construction of plasmid KSH126 
(FIG. 3) used for the introduction of an unmarked in-frame 
kshA gene deletion in R. erythropolis Strain SQ1 (rendering 
strain RG2) and strain RG8 (rendering strain RG9). 
The kshB gene encodes a 346 amino acid protein (KshB). 
Database similarity searches revealed that KshB showed high 
similarity to ferredoxin reductase components of multi-com 
ponent oxygenases. Highest similarity (56% identity: 85% 
similarity) was found with Rv3571 of M. tuberculosis 
(DDBJ/EMBL/GenBank accession no. A70606). 
Inactivation of ksha or kshB by unmarked gene deletion 
renders molecularly defined and genetically stable mutant 
strains capable of selective A'-dehydrogenation of AD pro 
ducing ADD that is not further metabolized due to absence of 
KSH activity (see WO 01/31050). Using the sacB counter 
selection system (described in WO 01/31050) three 
unmarked gene deletion mutant strains were constructed: a 
kshA mutant R. erythropolis RG2 using pKSH126 (FIG.3), a 
kshB mutant R. erythropolis RG4 using pKSH212 (FIG. 4) 
and a kstD kstD2 kshA mutant R. erythropolis RG9. Strains 
RG2 and RG4 are derived from R. erythropolis SQ1. Strain 
RG9 is derived from kstD kstD2 mutant R. erythropolis RG8 
using pKSH126 (FIG. 3). Strain RG8 lacks both 3-ketoster 
oid A'-dehydrogenase isoenzymes (KSTD1 and KSTD2: 
described in WO 01/31050). 
Thus, another aspect of this invention is a microorganism 
blocked in 3-ketosteroid 9C-hydroxylase activity character 
ized in that it is a genetically modified microorganism, in 
particular of the family of Actinomycetales, preferably of the 
Rhodococcus genus and most preferred of Rhodococcus 
erythropolis. Also preferred is a strain, wherein at least one 
gene encoding 3-ketosteroid A'-dehydrogenase activity is 
inactivated, preferably by unmarked gene deletion. In par 
ticular preferred are the strains RG2, RG4 and RG9. 
Also an aspect of the present invention is a method to 
construct a genetically modified strain of a steroid degrading 
microorganism lacking the ability to degrade the steroid 
nucleus, the method comprising inactivation of the genes 
encoding KSH-activity, preferably the genekshA and/or the 
gene kshB. Preferably, the inactivation of the gene(s) is 
accomplished by targeted, preferably unmarked, gene dele 
tion. 
A further aspect of the present invention is the use of a 
genetically modified microorganism in steroid A'-dehydro 
genation, in particular in the preparation of 1,4-androstadi 
ene-3,17-dione and prednisolone. Preferably, the microor 
ganism for Such use has been obtained by targeted gene 
inactivation, preferably umarked gene deletion, of the genes 
encoding KSH-activity in a microorganism of the family of 
Actinomycetales, preferably the gene kshA and/or the gene 
kshB. Preferred microorganism for this use is selected from 
the genetically modified strains RG2, RG4 and RG9. 
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The micro-organism strains Rhodococcus erythropolis 
RG2, RG4 and RG9 have been deposited at the Deutsche 
Sammlung von Mikroorganismen und Zellkulturen GmbH 
(DSMZ), Mascheroder Weg 1b, D-38124 Braunschweig, 
Germany under the accession numbers DSM 14544, DSM 
14545 and DSM 14546, respectively. These deposits have 
been made under the terms of the Budapest Treaty. 
Methods to construct vehicles to be used in the mutagen 
esis protocol are well known (Sambrook et al., Molecular 
Cloning: a Laboratory Manual, Cold Spring Harbor Labora 
tory Press, Cold Spring Harbor, latest edition). Furthermore, 
techniques for site directed mutagenesis, ligation of addi 
tional sequences, PCR, sequencing of DNA and construction 
of suitable expression systems are all, by now, well known in 
the art. Portions or all of the DNA encoding the desired 
protein can be constructed synthetically using standard Solid 
phase techniques, preferably to include restriction sites for 
ease of ligation. 
Modifications and variations of the method for introducing 
disrupted gene mutations, targeted gene inactivation, and in 
particular unmarked gene deletion as well as transformation 
and conjugation will be obvious to those skilled in the art 
from the detailed description of the invention. Such modifi 
cations and variations are intended to come within the scope 
of present application. A person skilled in the art will under 
stand how to use the methods and materials described and 
referred to in this document in order to construct micro 
organisms lacking KSH activity. 
The following examples are illustrative for the invention 
and should in no way be interpreted as limiting the scope of 
the invention. 
LEGENDS TO FIGURES 
FIG.1. The pZErO-2.1 (curved thin line) based Rhodococ 
cus-E. coli shuttle vector pRESQ used for constructing a 
genomic library of R. erythropolis RG1. rep: 2.5 kb region of 
pMVS301 coding for autonomous replication in Rhodococ 
cus sp (thick curved line). lacZ-ccdB: marker for positive 
selection in E. coli. aphII: kanamycin resistance marker for 
selection in Rhodococcus and E. coli. 
FIG. 2. Strategy for the separate cloning and identification 
of the kshA and kshB genes encoding KSH activity in R. 
erythropolis SQ1 by functional complementation of UV 
mutant strains RG1-UV39 (A) and RG1-UV26 (B), respec 
tively, using several pRESQ derived constructs. 
FIG. 3. (A) Overview of the 2.6 kb DNA fragment of R. 
erythropolis SQ1 encoding kshA and its 4.1 kb counterpart in 
R. erythropolis TA421. The grey bar of ORF12, together with 
the black arrow (proposed size of ORF12 by Maeda et al. 
(1995)), represents the actual size of ORF12 in R. erythropo 
lis TA421, which is identical (97%) to kshA. The “X” indi 
cates the point of merger of the two sequences. (B) Scheme of 
the theoretically merged nucleotide sequences of the DNA 
fragments of strain SQ1 and strain TA421, and its use in the 
construction of plasmid pKSH126 for unmarked in-frame 
kshA gene deletion in strain SQ1 and strain RG8. Numbers 
1-4 indicate the primers used to obtain PCR products 1 and 2 
for the construction of plasmid pKSH126 used for ksha 
unmarked gene deletion in parent strain SQ1 and kstDkstD2 
mutant strain RG8. 
FIG. 4. Cloning scheme for the construction of plasmid 
pKSH212 used in the construction of kshB unmarked gene 
















Construction of the pRESQ Shuttle Vector. 
A pZErO-2.1 (Invitrogen Corp. San Diego, Calif.) deriva 
tive was constructed in which the BamHI site was replaced by 
a BglII site (FIG. 1). A SacI-StuI fragment of pZErO-2.1, 
containing the lacZ-ccdB gene, was duplicated by PCR using 
a mutagenic forward primer (5' ACCGAGCTC 
AGATCTACTAGTAACGGC 3', SEQID NO:3), containing 
the desired BglII restriction site (double underlined) and a 
SacI restriction site (underlined), and reverse primer (5'ATTC 
AGGCCTGACATTTATATTCCCC 3', SEQID NO:4) with a 
StuI restriction site (underlined). The obtained PCR product 
was digested with restriction enzymes SacI and StuI and 
ligated in SacI-StuIdigested pZErO-2.1 (pRES14). The aphII 
gene from pWJ5 (Jäger, W. A. et al. (1992). J Bacteriol 174: 
5462-5465) was cloned as blunted HindIII-BamHI fragment 
(Klenow fill in) into EcoRV digested pBlueScript (II) KS to 
construct pFBsKm 1. The unique BglII site in pRsKm1 was 
destroyed by BglII digestion followed by Klenow fill in 
(pRES4). The amplicillin cassette present in pRES4 was 
removed by selfligation following BspHIdigestion (pRES9). 
A 2.5 kb BglII-Xbal fragment ofpMVS301 (Vogt-Singer, M. 
F. et al., (1988) J. Bacteriol. 170:638-645), containing the 
region for autonomous replication in Rhodococcus sp., was 
subsequently ligated into BamHI-Xbal digested pRES9 to 
construct pRES11. Construction of pRESQ (6.55 kb) was 
completed by ligating a 4.15 kb BspHI/NcoI fragment of 
pRES11 into BspHI-NcoI digested pRES14. 
Example 1 
Inactivation of Steroid 9C.-Hydroxylase Activity by 
UV Mutagenesis 
Late exponential phase R. erythropolis RG1 (=kstD 
mutant) cells (2:10 CFUsml") grown in 10 mM glucose 
mineral medium were sonicated for a short period of time to 
obtain single cells. Diluted (10) samples were spread on 
glucose mineral agar medium and irradiated for 15-20 sec 
with a UV lamp (Philips TAW 15W) at a distance of 27 cm, on 
average resulting in 95% killing of cells. After 4 days of 
incubation, colonies that had appeared were replica plated on 
AD (0.5 gl' solubilized in DMSO (50 mg ml)) mineral 
agar medium. A screening for AD(D) growth deficient 
mutants of R. erythropolis RG1 able to grow on 9CHAD 
mineral medium yielded 2 mutants that were clearly impaired 
in the KSH reaction. These mutants, designated strain RG1 
UV26 and strain RG1-UV39, showed no growth after 3-4 
days with either AD or ADD as sole carbon and energy 
source, while growth on 9CHAD mineral agar medium was 
normal. 
Example 2 
Cloning and Molecular Characterization of ksha and 
kshB 
The R. erythropolis strain RG1 gene library was introduced 
into strain RG1-UV39 by electrotransformation to comple 
ment its mutant phenotype (FIG. 2). A clone was isolated 
containing a 6 kb insert (pKSH 101) that was able to restore 
growth of strain RG1-UV39 on AD mineral agar medium. 
Restriction enzyme mapping analysis, Subcloning in pRESQ 
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and Subsequent complementation experiments resulted in 
identification of a 1.8 kb BamHI-Sau3A DNA fragment 
(pKSH 106) that was still able to complement strain RG1 
UV39 (FIG.2). This 1.8 kb insert was cloned into pBlueScript 
(II) KS and its nucleotide sequence determined. Nucleotide 
sequence analysis revealed a single 1,197 nt ORF (kshA, 
499-1695 of SEQ ID NO: 1) encoding a putative protein of 
398aa (KshA). 
Complementation of R. erythropolis RG1-UV26 with the 
strain RG1 gene library resulted in isolation of clone 
pKSH200 able to restore growth of strain RG1-UV26 on AD 
mineral agar medium (FIG. 2). By Subsequent restriction 
mapping analysis, Subcloning and complementation experi 
ments of pKSH200 we identified a 2.8 kb BglII-Sau3A frag 
ment (pKSH202) which was still able to restore the mutant 
phenotype of strain RG1-UV26 (FIG. 2). This fragment was 
subcloned into pEBlueScript (II) KS and its nucleotide 
sequence was determined. The ORF responsible for comple 
menting the RG1-UV26 mutant phenotype was identified 
from a Subsequent complementation experiment. An Asp718 
restriction site mapped on the 2.8 kb fragment was used to 
construct pKSH205, which could no longer complement the 
mutant phenotype (FIG. 2). The Asp718 restriction enzyme 
thus is located within the ORF responsible for complemen 
tation. The identified ORF of 1,041 nt was designated kshB 
(387-1427 of SEQID NO:2: GC content, 62.3%) encoding a 
putative protein of 346 amino acids with a calculated molecu 
lar weight of 37.1 kDa (KshB). 
Example 3 
Unmarked Gene Deletion of ksha in R. erythropolis 
SQ1 
For unmarked in-frame gene deletion of ksha (Aksha) 
pKSH126 was constructed. A 1.3 kb fragment (PCR product 
1) was obtained from pKSH 101 using a primer (FIG.3 primer 
1) annealing to sequences upstream ofkshA (5' CGCGGGC 
CCATCGAGAGCACGTT 3', SEQ ID NO:5), and a primer 
(FIG. 3 primer 2) annealing to the 5'-end of the ksha gene (5' 
GCGCCCGGGTCCGAGTGCCATGTCTTC 3', SEQ ID 
NO:6) containing a Small site (underlined). Primers for PCR 
product 2 were developed using the nucleotide sequence of 
the merged sequences of strain SQ1 and strainTA421 (DDBJ/ 
EMBL/GenBank accession no. D88013). PCR product 2 
(840 bp) was obtained from SQ1 chromosomal DNA using 
forward primer (FIG.3 primer3) annealing to the 3' end of the 
kshA gene (5' GCG 
CCCGGGACAACCTCCTGATTCGCAGTC 3', SEQ ID 
NO:7), including a SmaI restriction site (underlined), and 
reverse primer (FIG. 3 primer 4) annealing to ORF11 (5' 
GCGTCTAGAGTGGAAGAGCATTCCCTCGCA 3', SEQ 
ID NO:8), including a Xbal restriction site (underlined). The 
SmaI restriction site was introduced to give an in-frame dele 
tion of ksha following ligation of this PCR fragment behind 
the 5'-truncated ksha gene from PCR product 1. Finally, a 
2.05 kb SalI-Xbal fragment from pKSH125 was ligated into 
pK18mobsacB vector (pKSH126). 
Unmarked in-frame deletion of the ksha gene was 
obtained by introducing the mutagenic vector pKSH126 in 
strain SQ1 followed by sacB counter selection (WO 
01/31050). Wild type kshA gene was reduced to an ORF 
(Aksha) of 30 nt, encoding only 9 amino acids (MALG 
PGTTS). Gene deletion of ksha was confirmed by Southern 
analysis of BamHI digested chromosomal DNA using the 2 













DNA fragment was reduced to 0.88 kb in the gene deletion 
mutant Strains. The resulting Strain is designated R. erythro 
polis RG2. 
Example 4 
Unmarked Gene Deletion of kshB in R. erythropolis 
SQ1. 
For unmarked in-frame gene deletion of kshB construct 
pKSH212 was made (FIG. 4). For this purpose pKSH201 was 
fused to a PCR product (1,275bp) obtained from pKSH202 as 
a template. PCR product was obtained with forward primer 5' 
GCGGGTACCGATCGCCTGAAGATCGAGT 3' (SEQ ID 
NO:9) and reverse primer 5' GCGAAGCTTGCCG 
GCGTCGCAGCTCTGTG 3' (SEQ ID NO:10) and ligated 
(blunt) into EcoRV digested pBlueScript(II) KS (pKSH210). 
At the 5'-terminal end of this PCR product an Asp718 restric 
tion site, preceding the stop codon of kshB (see forward 
primer), was introduced to ensure proper in-frame deletion of 
kshB after ligation with the Asp718 restriction site of 
pKSH201. At the 3'-terminal end a HindIII restriction site 
(see reverse primer) was added, compatible to the HindIII 
restriction site of pKSH201, for cloning purposes. PCR prod 
uct was isolated from pKSH210 by Asp718-HindIII digestion 
(1,263 bp) and ligated into Asp718-HindIII digested 
pKSH201 (FIG. 2) (pKSH211), thereby introducing the 
desired kshB in-frame deletion (FIG. 4). Finally, a BamHI 
HindIII DNA fragment (2.2 kb) containing the kshB deletion 
was ligated into pK18mobsacB (see WO 01/31050) digested 
with BamHI and HindIII (pKSH212). 
Plasmid pKSH212 was introduced into R. erythropolis 
SQ1 by conjugation using Escherichia coli S17-1. Unmarked 
kshB gene deletion was obtained using the sacB counter 
selectable system (WO 01/31050). Potential kshB mutants 
were screened by replica plating on AD mineral agar plates, 
which enabled us to isolate kshB mutants unable to grow on 
AD. Southern analysis was performed on Asp718 digested 
chromosomal DNA of wild type and three AD growth defi 
cient mutants. Hybridization with the complete kshB gene 
showed that kshB was not present in the genome of the 
putative kshB mutants. A clear hybridization signal (4.3 kb 
fragment) was exclusively found with wild type chromo 
somal DNA. Additional Southern analysis with an alternative 
probe, being the 2.2 kb insert of pKSH212 comprising both 
flanking regions of kshB, furthermore confirmed kshB gene 
deletion: a 4.3 kb Asp718 wild type DNA fragment contain 
ing the kshB gene was reduced to 3.3 kb in a kshB mutant, 
demonstrating replacement of the 1,041 bp kshB gene by a 
kshB in-frame remnant of 30 nt (encoding MTTVEVPIA). 
The resulting strain is designated R. erythropolis RG4. 
Example 5 
Use of a Genetically Modified Strains RG1-UV26, 
RG1-UV39, RG2, RG4 and RG9 in Steroid 
A'-dehydrogenation 
Strains RG2 and RG4 were plated on mineral agar media 
containing AD, ADD or 9CHAD as sole carbon and energy 
source. Both strains showed no growth on AD(D), whereas 
growth on 9OHAD was comparable to strain SQ1. These 
phenotypes are in agreement with those found with UV 
mutant strains RG1-UV26 and RG1-UV39. Bioconversion of 
AD (1 gl') with strain SQ1 results in AD utilization but not 
in accumulation of ADD or other metabolites. Bioconversion 
of AD (1 gl') by strain RG2 or strain RG4 resulted in 
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- Continued 
attcaggcct gacatttata t t c coc 
<210 SEQ ID NO 5 
<211 LENGTH: 23 
&212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: primer 
<4 OO SEQUENCE: 5 
cgcgggcc catcgaga.gcac gtt 
<210 SEQ ID NO 6 
<211 LENGTH: 27 
&212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: primer 
<4 OO SEQUENCE: 6 
gcgc.ccgggit ccgagtgcca ttct tc 
<210 SEQ ID NO 7 
<211 LENGTH: 30 
&212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: primer 
<4 OO SEQUENCE: 7 
gcgc.ccggga caacct Cotg attcgcagtic 
<210 SEQ ID NO 8 
<211 LENGTH: 30 
&212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: primer 
<4 OO SEQUENCE: 8 
gcgt.ctagag taagagca tt.ccct cqca 
<210 SEQ ID NO 9 
<211 LENGTH: 28 
&212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: primer 
<4 OO SEQUENCE: 9 
gcgggit accg atcgc.ctgaa gat.cgagt 
<210 SEQ ID NO 10 
<211 LENGTH: 29 
&212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: primer 
<4 OO SEQUENCE: 10 
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We claim: 
1. A genetically modified microorganism blocked in 3-ke 
tosteroid 9C.-hydroxylase activity, wherein the microorgan 
ism comprises at least one inactivated gene encoding KSH 
activity selected from the group consisting of the kshA gene 
of SEQ ID NO:1 and the kshB gene of SEQ ID NO:2, and 
wherein the microorganism is of the order of Actinomyc 
etales. 
2. The microorganism of claim 1, being of the Rhodococ 
CuS genus. 
3. The microorganism according to claim 1, being selected 
from the genetically modified microorganisms RG2, RG4 
and RG9. 
4. A method to construct a genetically modified strain of a 
steroid degrading microorganism of the order of Actinomyc 
etales lacking the ability to degrade the steroid nucleus, the 
method comprising inactivation of at least one gene encoding 
KSH-activity selected from the group consisting of the ksha 




5. The method of claim 4, wherein the inactivation of the 
gene(s) is accomplished by targeted gene deletion. 
6. The method of claim 5, wherein the inactivation of the 
gene(s) is accomplished by targeted, unmarked, gene dele 
tion. 
7. The microorganism of claim 1, wherein the microorgan 
ism further comprises at least one inactivated gene encoding 
3-ketosteroid A'-dehydrogenase activity. 
8. The microorganism of claim 1, wherein the inactivated 
gene encoding KSH-activity is the ksha gene of SEQ ID 
NO:1. 
9. The microorganism of claim 1, wherein the inactivated 
gene encoding KSH-activity is the kshB gene of SEQID NO: 
2. 
10. The method of claim 4, wherein the method further 
comprises inactivation of at least one gene encoding 3-keto 
steroid A'-dehydrogenase activity. 
k k k k k 
